Literature DB >> 8523034

Spinocerebellar ataxia, type 3 (SCA3) is genetically identical to Machado-Joseph disease (MJD).

G Haberhausen1, M S Damian, F Leweke, U Müller.   

Abstract

Spinocerebellar ataxia, type 3 (SCA3) and Machado-Joseph disease (MJD) are two clinically distinct representatives of the heterogeneous group of autosomal dominant cerebellar ataxias. Assignment of the disease genes to the same region of the long arm of chromosome 14 in both SCA3 and MJD suggested that these two disorders are genetically identical. The recent identification of a trinucleotide (CAG) repeat expansion in a gene underlying MJD facilitates assessment of this hypothesis. We analysed the MJD gene in members of a family with characteristic features of SCA3 and no symptoms typical of MJD. We found the same trinucleotide repeat expansion within the gene that was previously described in patients with MJD. The findings demonstrate that SCA3 and MJD are genetically identical in spite of their pronounced clinical differences. Furthermore, we demonstrate a striking variation in the copy number of the CAG repeat among affected members of the same family.

Entities:  

Mesh:

Year:  1995        PMID: 8523034     DOI: 10.1016/0022-510x(95)90927-i

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

3.  Co-chaperone HSJ1a dually regulates the proteasomal degradation of ataxin-3.

Authors:  Xue-Chao Gao; Chen-Jie Zhou; Zi-Ren Zhou; Yu-Hang Zhang; Xue-Ming Zheng; Ai-Xin Song; Hong-Yu Hu
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

Review 4.  Neurogenetic diseases: molecular diagnosis and therapeutic approaches.

Authors:  U Muller; M B Graeber
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

5.  Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.

Authors:  Mercedes Prudencio; Hector Garcia-Moreno; Karen R Jansen-West; Rana Hanna Al-Shaikh; Tania F Gendron; Michael G Heckman; Matthew R Spiegel; Yari Carlomagno; Lillian M Daughrity; Yuping Song; Judith A Dunmore; Natalie Byron; Björn Oskarsson; Katharine A Nicholson; Nathan P Staff; Sorina Gorcenco; Andreas Puschmann; João Lemos; Cristina Januário; Mark S LeDoux; Joseph H Friedman; James Polke; Robin Labrum; Vikram Shakkottai; Hayley S McLoughlin; Henry L Paulson; Takuya Konno; Osamu Onodera; Takeshi Ikeuchi; Mari Tada; Akiyoshi Kakita; John D Fryer; Christin Karremo; Inês Gomes; John N Caviness; Mark R Pittelkow; Jan Aasly; Ronald F Pfeiffer; Venka Veerappan; Eric R Eggenberger; William D Freeman; Josephine F Huang; Ryan J Uitti; Klaas J Wierenga; Iris V Marin Collazo; Philip W Tipton; Jay A van Gerpen; Marka van Blitterswijk; Guojun Bu; Zbigniew K Wszolek; Paola Giunti; Leonard Petrucelli
Journal:  Sci Transl Med       Date:  2020-10-21       Impact factor: 17.956

6.  Spinocerebellar ataxia type 1 in Russia.

Authors:  S N Illarioshkin; P A Slominsky; I V Ovchinnikov; E D Markova; N I Miklina; S A Klyushnikov; M Shadrina; N V Vereshchagin; S A Limborskaya; I A Ivanova-Smolenskaya
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

Review 7.  SCA3: neurological features, pathogenesis and animal models.

Authors:  Olaf Riess; Udo Rüb; Annalisa Pastore; Peter Bauer; Ludger Schöls
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

8.  Basic and translational neuro-ophthalmology of visually guided saccades: disorders of velocity.

Authors:  Sushant Puri; Aasef G Shaikh
Journal:  Expert Rev Ophthalmol       Date:  2017-11-28

Review 9.  Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.

Authors:  Melvin M Evers; Lodewijk J A Toonen; Willeke M C van Roon-Mom
Journal:  Mol Neurobiol       Date:  2013-11-29       Impact factor: 5.590

10.  Genes and genetic testing in hereditary ataxias.

Authors:  Erin Sandford; Margit Burmeister
Journal:  Genes (Basel)       Date:  2014-07-22       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.